Results 111 to 120 of about 14,850 (194)

Renal Protection at a Metabolic Cost: A Systematic Review and Meta‐Analysis of Perioperative Use of Sodium–Glucose Cotransporter 2 Inhibitors

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 2, March 2026.
Across 246,542 surgical patients, perioperative SGLT2 inhibitor use was associated with a lower odds of acute kidney injury and mortality. In contrast, ketoacidosis outcomes (DKA and euglycemic ketoacidosis) showed no statistically significant difference overall, but appeared more frequent in selected sensitivity and subgroup analyses, consistent with ...
Elsayed Balbaa, Ahmed Farid Gadelmawla, Ahmed Ibrahim, AlMothana Manasrah, Ahmed Elbataa, Abdalhakim Shubietah, Mohamed S. Elgendy, Ahmed Sobhy, Ahmed Mansour, Ameer Awashra, Nourhan N. Elguindy, Mohammad Bazzazeh, Abdelhamid Ben‐Selma   +12 more
wiley   +1 more source

Efficacy of SGLT2 Inhibitors on Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 2, March 2026.
SGLT2 inhibitor therapy was associated with a significantly lower risk of the composite outcome of all‐cause mortality or heart failure hospitalization at one year, as well as each component individually. ABSTRACT Background Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular (CV) outcomes in patients with heart failure (HF) and ...
Shaikh Muhammad Daniyal, Naveen Murad Khatoon, Anas Rasool, Isbah Gul, Sabula Tabish, Shireen Asifa, Ayan Khalid, Zunaira Aftab, Muhammad Burhan, Syeda Laiba Fahim, Habiba Tauqir Gondal, Muhammad Asfandyar Nadir, Syed Zaeem Ahmed, Danish Ali Ashraf, Somaiya Ahmed   +14 more
wiley   +1 more source

Boscisucrophage: A Natural SGLT1/2 Inhibitor From Boscia senegalensis for Managing Type 2 Diabetes

Food Science &Nutrition, Volume 14, Issue 3, March 2026.
Boscisucrophage (BSP) significantly reduced blood glucose and HbA1c, increased urine glucose excretion, and improved functional symptoms in T2DM patients resistant to oral antihyperglycemic drugs. BSP showed no adverse effects on liver or kidney function.
Bruno Eto, Amal Elrherabi, Fahd A. Nasr, Joe Miantezila Basilua, Ahlam Outman, Rosette Christelle Ndjip, Mohamed Bouhrim, Mohammed Al‐zharani, Ashraf Ahmed Qurtam, Brahim Ibet, Bernard Gressier, Jehan‐François Desjeux   +11 more
wiley   +1 more source

A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy. [PDF]

Cureus
Erande SG, Raykantiwar A, Shejole V, Gr R, Maiti A, Kartheek ASV, Hanifah M, Giri R, Gadve S, Ray A, Thakkar K, Sharma B, Kant S, Verma A, Yadav Y, Prajapati H, Desai H.   +16 more
europepmc   +1 more source

Assessment of Quality of Care Provided for Patients Receiving Post‐Myocardial Infarction Care at Selected Cardiac Clinics in Sulaymaniyah: Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background According to global projections, by the year 2050, ischemic heart disease will remain the leading cause of cardiovascular deaths with hypertension as a leading modifiable risk factor for mortality. Improving quality care for patients with acute myocardial infarction (MI) is associated with improved outcomes. Aims There is inadequate
Banaz Sadiq Elias, Yara Sarwar Hamid, Mende Mensa Sorato   +2 more
wiley   +1 more source

Effects of dapagliflozin on main pulmonary artery diameter in patients undergoing mitral valve replacement: a retrospective observational study. [PDF]

Front Cardiovasc Med
Wang D, Liu P, Chen X, Hu H, Wang H, Zhang Z, Liu X.   +6 more
europepmc   +1 more source

LKB1–AMPK Signaling Pathway in Cardiovascular and Other Diseases

MedComm, Volume 7, Issue 3, March 2026.
The LKB1–AMPK pathway has a central regulatory role in various diseases. Dysfunction of this pathway can lead to pathological processes in cardiovascular diseases (atrial fibrillation, myocardial infarction, myocardial hypertrophy, atherosclerosis), metabolic diseases (diabetes and kidney disease), neurodegenerative diseases (Alzheimer's disease ...
Zhuo Chen, Qin Yang, Guo‐Wei He
wiley   +1 more source

Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease. [PDF]

J Vet Intern Med
Massey LK, Ward JL, Crooks AV, Guillot E, Ceron J, Rubio C, Convey V, Tropf M, Ciou MJ, Mochel JP, Oyama MA.   +10 more
europepmc   +1 more source

The DYRK Family: A Key Regulator of Metabolic Homeostasis and Its Therapeutic Potential in Kidney Diseases

MedComm – Future Medicine, Volume 5, Issue 1, March 2026.
The DYRK family, a pivotal metabolic homeostasis regulator, mediates crosstalk between metabolic disorders and CKD via subtype‐specific mechanisms: DYRK1A drives diabetic (CKD risk), DYRK1B exacerbates metabolic renal injury, DYRK2 contributes to renal osteodystrophy, while DYRK3/4 remain unelucidated.
Yixuan Zhu, Pengfei Qiao, Yukun Gan, Xiushuo Fu, Xiayue Huang, Sirui Sun, Yafei Gou, Wenjie Xia, Feng Ma, Limin Liu   +9 more
wiley   +1 more source

GLUT5-Driven Gut-Liver Axis Injury Mediating Olanzapine-Induced NAFLD and Dapagliflozin Intervention. [PDF]

Drug Des Devel Ther
Chen X, Zhang Y, Wang J, Chen L, He SM, Wang DD.   +5 more
europepmc   +1 more source